The estimated Net Worth of Caroline Dorsa is at least $2.86 million dollars as of 10 June 2021. Ms. Dorsa owns over 1,000 units of Illumina Inc stock worth over $1,061,180 and over the last 21 years she sold ILMN stock worth over $1,294,522. In addition, she makes $501,477 as Independent Director at Illumina Inc.
Caroline has made over 12 trades of the Illumina Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently she sold 1,000 units of ILMN stock worth $450,000 on 10 June 2021.
The largest trade she's ever made was exercising 80,309 units of Illumina Inc stock on 4 August 2015 worth over $2,487,170. On average, Caroline trades about 2,364 units every 74 days since 2004. As of 10 June 2021 she still owns at least 8,501 units of Illumina Inc stock.
You can see the complete history of Ms. Dorsa stock trades at the bottom of the page.
Caroline D. Dorsa is an Independent Director of Illumina, Inc. Ms. Dorsa has held a number of senior management positions at Merck & Co. Inc, including Senior Vice President of Marketing Strategy and Integration, and Vice President and Treasurer, where she also oversaw investor relations, financial planning for manufacturing and tax. Most recently, as Executive Vice President and CFO at Public Service Enterprise Group, Ms. Dorsa led the finance, business development, and investor relations teams. She is a Director of Biogen Inc. and Intellia Therapeutics, Inc. and a trustee of the Goldman Sachs MLP Income Opportunities Fund and the Goldman Sachs MLP and Energy Renaissance Fund. In addition to her service at Merck & Co. Inc. and at Public Service Enterprise Group, Ms. Dorsa served as Senior Vice President and CFO of Avaya, Inc. She received her B.A. from Colgate University and her M.B.A. from Columbia University.
As the Independent Director of Illumina Inc, the total compensation of Caroline Dorsa at Illumina Inc is $501,477. There are 12 executives at Illumina Inc getting paid more, with Mostafa Ronaghi having the highest compensation of $3,541,310.
Caroline Dorsa is 60, she's been the Independent Director of Illumina Inc since 2017. There are 6 older and 15 younger executives at Illumina Inc. The oldest executive at Illumina Inc is John Thompson, 71, who is the Lead Independent Director.
Over the last 21 years, insiders at Illumina Inc have traded over $412,190,379 worth of Illumina Inc stock and bought 13,386 units worth $1,243,499 . The most active insiders traders include John Wendell Thompson, Jay T Flatley et Robert Nelsen. On average, Illumina Inc executives and independent directors trade stock every 5 days with the average trade being worth of $954,700. The most recent stock trade was executed by Jacob Thaysen on 22 February 2024, trading 7,330 units of ILMN stock currently worth $991,676.
at illumina, our goal is to apply innovative technologies and revolutionary assays to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. these studies will help make the realization of personalized medicine possible. with such rapid advances in technology taking place, it is mission critical to have solutions that are not only innovative, but flexible, scalable, and complete with industry-leading support and service. as a global company that places high value on collaborative interactions, rapid delivery of solutions, and prioritizing the needs of its customers, we strive to meet this challenge. illumina’s innovative, array-based solutions for dna, rna, and protein analysis serve as tools for disease research, drug development, and the development of molecular tests in the clinic.
Illumina Inc executives and other stock owners filed with the SEC include: